1. Serinol-Based Benzoic Acid Esters as New Scaffolds for the Development of Adenovirus Infection Inhibitors: Design, Synthesis, and In Vitro Biological Evaluation
- Author
-
Lara Mendolia, Sarah Mazzotta, Margarita Vega-Holm, Jerónimo Pachón, Fernando Iglesias-Guerra, José M. Vega-Pérez, Judith Berastegui-Cabrera, Javier Sánchez-Céspedes, Gabriele Carullo, Francesca Aiello, Marta Carretero-Ledesma, Ministerio de Ciencia, Innovación y Universidades (España), Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), Red Española de Investigación en Patología Infecciosa, European Commission, Spanish Adenovirus Network, and Junta de Andalucía
- Subjects
0301 basic medicine ,Drug ,Human cytomegalovirus ,Adenoviridae Infections ,media_common.quotation_subject ,030106 microbiology ,Antivirals agents ,Context (language use) ,Benzoic acid esters ,Microbiology ,Propanolamines ,03 medical and health sciences ,chemistry.chemical_compound ,Viral entry ,Humans ,Medicine ,Adenovirus ,Chemical synthesis ,Adenovirus infection ,Pathogen ,IC50 ,media_common ,business.industry ,virus diseases ,Esters ,adenovirus ,antivirals agents ,benzoic acid esters ,chemical synthesis ,serinol derivatives ,urea derivatives ,Propylene Glycols ,Benzoic Acid ,Serinol derivatives ,medicine.disease ,eye diseases ,030104 developmental biology ,Infectious Diseases ,chemistry ,business ,Urea derivatives ,Cidofovir - Abstract
Over the years, human adenovirus (HAdV) has progressively been recognized as a significant viral pathogen. Traditionally associated with self-limited respiratory, gastrointestinal, and conjunctival infections, mainly in immunocompromised patients, HAdV is currently considered to be a pathogen presenting significant morbidity and mortality in both immunosuppressed and otherwise healthy individuals. Currently available therapeutic options are limited because of their lack of effectivity and related side effects. In this context, there is an urgent need to develop effective anti-HAdV drugs with suitable therapeutic indexes. In this work, we identified new serinol-derived benzoic acid esters as novel scaffolds for the inhibition of HAdV infections. A set of 38 compounds were designed and synthesized, and their antiviral activity and cytotoxicity were evaluated. Four compounds (13, 14, 27, and 32) inhibited HAdV infection at low micromolar concentrations (2.82–5.35 μM). Their half maximal inhibitory concentration (IC50) values were lower compared to that of cidofovir, the current drug of choice. All compounds significantly reduced the HAdV DNA replication process, while they did not block any step of the viral entry. Our results showed that compounds 13, 14, and 32 seem to be targeting the expression of the E1A early gene. Moreover, all four derivatives demonstrated a significant inhibition of human cytomegalovirus (HCMV) DNA replication. This new scaffold may represent a potential tool useful for the development of effective anti-HAdV drugs., This work has been supported by Ministerio de Ciencia, Innovación y Universidades, Plan Estatal 2017-2020 Retos-Proyectos I+D+i (PID2019-104767RB-I00), Ministerio de Economı́a y Competitividad, Plan Estatal 2013-2016 Retos-Proyectos I + D + i (CTQ2016-78580-C2-2-R) and by Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009), cofinanced by European Development Regional Fund “A way to achieve Europe”, the Instituto de Salud Carlos III, Proyectos de Investigación en Salud (PI17/01055; PI18/01191) and Proyectos de Desarrollo Tecnológico en Salud (DTS17/00130), the Spanish Adenovirus Network (AdenoNet, BIO2015/68990-REDT), and the program “Nicolás Monardes” (C-0059-2018), Servicio Andaluz de Salud, Junta de Andalucía. M.V.-H. also thanks Ministerio de Economı́a y Competitividad, Plan Estatal 2013-2016 Excelencia I+D+i (CTQ2016-78703-P).
- Published
- 2021